Iptacopan Hydrochloride Monohydrate is a novel, orally administered complement factor B inhibitor used to treat rare blood disorders, including paroxysmal nocturnal hemoglobinuria, and specific kidney… Read more
Iptacopan Hydrochloride Monohydrate is a novel, orally administered complement factor B inhibitor used to treat rare blood disorders, including paroxysmal nocturnal hemoglobinuria, and specific kidney conditions such as atypical hemolytic uremic syndrome. By selectively blocking the alternative complement pathway, this therapeutic agent prevents uncontrolled immune activation. This category encompasses a comprehensive selection of high-quality reference standards, including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled compounds specifically developed for this drug. Pharmaceutical laboratories rely on these specialized materials for accurate impurity profiling, rigorous quality control, and bioanalytical method validation throughout the drug development lifecycle. These analytical standards are essential for ensuring the precision and reliability of assays used to assess the efficacy and safety of this complement inhibitor during research and routine manufacturing.